Patent ID: 8383357
Filing Date: 2013-02-26
Classification: A61P,G01N

Abstract:
1. A method of predicting whether a cancer patient is afflicted with a tumor that will respond effectively to treatment with an EGFR kinase inhibitor, comprising: assessing the level of an epithelial biomarker expressed by cells of the tumor relative to the expression level of said biomarker in a control cell sample that is either an epithelial tumor cell or a mesenchymal-like tumor cell that has undergone an epithelial-to-mesenchymal transition; and determining whether said level is more similar to the high level of the biomarker in a tumor epithelial cell, or low level in a tumor mesenchymal-like cell that has undergone an epithelial-to-mesenchymal transition; and predicting if the tumor will respond effectively to treatment with an EGFR kinase inhibitor, wherein high expression levels of tumor cell epithelial biomarkers correlate with a tumor that will respond effectively to treatment with an EGFR kinase inhibitor, wherein the epithelial biomarker is one of phospho-14-3-3 epsilon, 14-3-3 sigma (Stratifin), phospho-serine/threonine phosphatase 2A, 4F2hc (CD98 antigen), adenine nucleotide translocator 2, annexin A3, ATP synthase beta chain, phospho-insulin receptor substrate p53/p54, Basigin (CD 147 antigen), phospho-CRK-associated substrate (p130Cas), Bcl-X, phospho-P-cadherin, phospho-calmodulin (CAM), Calpain-2 catalytic subunit, Cathepsin D, Cofilin-1, Calpain small subunit 1, Catenin beta-1, Catenin delta-1 (p 120 catenin), Cystatin B, phospho-DAZ-associated protein 1, Carbonyl reductase [NADPH], Diaphanous-related formin 1 (DRF 1), Desmoglein-2, Elongation factor 1-delta, Ezrin (p81), phospho-focal adhesion kinase 1, phospho-GRB2-associated binding protein 1, phospho-GRB2, GRP 78, Glutathione S-transferase P, 3-hydroxyacyl-CoA dehydrogenase, HSP70-1, eIF3 p 110, Leukocyte elastase inhibitor, Importin-4, Integrin alpha-6, Integrin beta-4, phospho-Cytokeratin 17, Cytokeratin 19, Casein kinase 1 alpha, Protein kinase C delta, phospho-Erbin, LIM and SH3 domain protein 1 (LASP-1), 4F21 c (CD98 light chain), L-lactate dehydrogenase A chain, phospho-LIN-7 homolog C, MAP (APC-binding protein EB 1), phospho-Met tyrosine kinase (HGF receptor), Mixed-lineage leukemia protein 2, Monocarboxylate transporter 4, Myosin-9, Myosin light polypeptide 6, Nicotinamide phosphoribosyltransferase, Niban-like protein (Meg-3), Ornithine aminotransferase, phospho-Occludin, Ubiquitin thiolesterase, PAF acetylhydrolase IB beta subunit, phospho-partitioning-defective 3 (PAR-3), phospho-programmed cell death 6-interacting protein, phospho-Programmed cell death protein 6, phospho-plakophilin-2, phospho-plakophilin-3, Protein phosphatase 1, Peroxiredoxin 5, Proteasome activator complex subunit 1, RuvB-like 1, S-100P, S-100L, Calcyclin, S100C, phospho-Sec23A, phospho-Sec23B, Lysosome membrane protein II (LIMP II), phospho-Amplaxin (EMS 1), SLP-2, Tumor calcium signal transducer 1, Transgelin-2, Transaldolase, Translationally controlled (TCTP), Tissue transglutaminase, Transmembrane protein Tmp21, Ubiquitin-conjugating enzyme E2 N, UDP-glucosyltransferase 1, phospho-p61-Yes, or phospho-Tight junction protein ZO-1, wherein the tumor is a human non-small cell lung cancer tumor, and wherein the EGFR kinase inhibitor comprises erlotinib.